G1 Believes Boehringer Is Better Bet To Sell Trilaciclib
Drops Plans To Market Alone In US
G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."
